Abstract
Epoxyeicosatrienoic acids (EET) are created by CYP450 epoxygenases and possess a wide variety of cardiovascular protective actions. Since their presence is transitory the synthesis of EET mimetics with longer lifetimes offers a potential route for cardiovascular drug development. While one such mimetic, an esterified EET analogue (EET‐8‐ZE), had no effect in SHR rats, further modification by amidation of the carboxylic group with aspartic acid (EET‐8‐ZE‐D) has been shown to reduce blood pressure in SHR rats (injected at 3mg/day; at Day 2 the MAPδ was ‐8±1.3 mmHg). From there we have developed an LC‐MS method for the detection of EET‐8‐ZE‐D in rat serum. A 200μl sample of rat serum was diluted with water to a total of 1ml then spiked with both EET‐8‐ZE‐D and deuterated‐EET standards; after adding acetic acid to a 20% concentration it underwent a chloroform/methanol liquid‐phase extraction. The organic phase was collected dried down under nitrogen, briefly resuspended in methanol then dried and suspended in 30ul acetonitrile. After reverse‐phase separation on an HPLC column (acetonitrile + 0.1% acetic acid against water + 0.1% acetic acid) the samples were run on an Agilent 1100 triple quadrupole MS, providing sufficient quantitative sensitivity to isolate 300pg. These data demonstrate that the EET‐8ZE‐D mimetic has in vivo cardiovascular activity and that EET‐8ZE‐D can be accurately measured in biological fluids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
